SCHEMBL6028150

SCHEMBL6028150

CC(C)(CO)NCCCOc1ccc2c(Nc3cn(CC(=O)Nc4cccc(F)c4F)nn3)ncnc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 15/20 0.52
AURKB Q96GD4 5/20 0.52
KIT P10721 3/20 0.43
PDGFRA P16234 3/20 0.43
CSF1R P07333 2/20 0.43
PDGFRB P09619 2/20 0.43
CYP3A4 P08684 1/20 0.40
EGFR P00533 2/20 0.39
KDR P35968 2/20 0.39
PLK4 O00444 1/20 0.39
CIT O14578 1/20 0.39
MUSK O15146 1/20 0.39
EPHB6 O15197 1/20 0.39
MAP3K7 O43318 1/20 0.39
RIPK2 O43353 1/20 0.39
STK10 O94804 1/20 0.39
MAP4K4 O95819 1/20 0.39
CHEK2 O96017 1/20 0.39
ABL1 P00519 1/20 0.39
ERBB2 P04626 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2051920 0.89 PDGFRB (0.54) AURKAAURKBKITPDGFRACSF1R
SCHEMBL6027668 0.89 AURKA (0.53) AURKAAURKBKITPDGFRACSF1R
SCHEMBL6027424 0.88 AURKA (0.51) AURKAAURKBKITPDGFRACSF1R
SCHEMBL6092376 0.87 AURKA (0.53) AURKAAURKBKITPDGFRACSF1R
SCHEMBL6027709 0.85 AURKA (0.71) AURKAAURKBKITPDGFRACSF1R
SCHEMBL6027357 0.85 AURKA (0.58) AURKAAURKBKITPDGFRACSF1R
SCHEMBL6091198 0.85 AURKA (0.56) AURKAAURKBKITPDGFRACSF1R
SCHEMBL6091058 0.85 AURKA (0.55) AURKAAURKBKITPDGFRACSF1R
SCHEMBL6091927 0.85 AURKA (0.57) AURKAAURKBKITPDGFRACSF1R
SCHEMBL6027436 0.85 AURKA (0.58) AURKAAURKBKITPDGFRACSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060178382-A1 Chinazoline derivatives as aurora kinase inhibitors ASTRAZENECA AB (SE) 2006-08-10 US claimed
EP-1644361-A1 CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS Astrazeneca AB (SE) 2006-04-12 EP disclosed
WO-2004113324-A1 CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS ASTRAZENECA AB (SE) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178382-A1 Chinazoline derivatives as aurora kinase inhibitors AURKA, AURKC, AURKB AURKA 1/4885AURKB 3/4885KIT 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.